Pirnie R, P Gillespie K, Mesaros C, Blair IA. Reappraisal of oxidized HMGB1 as a mediator and biomarker. Future Sci OA. 2023 Feb 10;8(10):FSO828. doi: 10.2144/fsoa-2022-0052. PMID: 36874369; PMCID: PMC9979160.
Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Yip O, Rao A, Kim MJ, Nelson MR, Wang YH, Grone B, Hao Y, Thomas R, Zilberter M, Yoon SY, Arriola P, Huang Y. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Rep. 2023 Oct 31;42(10):113252. doi: 10.1016/j.celrep.2023.113252. Epub 2023 Oct 19. PMID: 37863057.
Competition in the TYK2 drug market is intensifying, and Pfizer will sell 2 drugs under development
https://worldwidechemicallabs.us/
Competition in the TYK2 drug market is intensifying, and Pfizer will sell 2 drugs under development
https://worldwidechemicallabs.us/
Pirnie R, P Gillespie K, Mesaros C, Blair IA. Reappraisal of oxidized HMGB1 as a mediator and biomarker. Future Sci OA. 2023 Feb 10;8(10):FSO828. doi: 10.2144/fsoa-2022-0052. PMID: 36874369; PMCID: PMC9979160.
Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Yip O, Rao A, Kim MJ, Nelson MR, Wang YH, Grone B, Hao Y, Thomas R, Zilberter M, Yoon SY, Arriola P, Huang Y. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Rep. 2023 Oct 31;42(10):113252. doi: 10.1016/j.celrep.2023.113252. Epub 2023 Oct 19. PMID: 37863057.
What about HMGB1 as a potential target. Intriguing recent Alzheimer's paper.